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Abstract
Obesity represents a major global challenge from both healthcare and 
economic perspectives. Although lifestyle modifications aimed at 
reducing calorie intake and increasing energy expenditure remain the 
cornerstone of obesity management, pharmacotherapy can serve as a 
useful adjunct. Until recently, orlistat was the only medication registered 
for the treatment of obesity in the European Union (EU). A deeper 
understanding of the complexity of energy homeostasis has resulted in 
new pharmacological options for weight reduction. In 2015, two new anti-
obesity drugs were approved in the EU. These are a fixed combination of 
naltrexone/bupropion (Mysimba®) and liraglutide at a dose of 3.0 mg 
(Saxenda®). In addition, lorcaserin (Belviq®) and a fixed combination of 
phentermine/topiramate (Qsymia®) were introduced into the US market 
in 2012. However, the European Medicines Agency did not approve their 
use in the EU. The burden of previous weight loss agents that have been 
withdrawn due to safety concerns underlines the need for caution and 
close follow-up of patients undergoing pharmacological interventions for 
obesity treatment. This article provides an overview of the efficacy and 
safety of currently available weight loss pharmacotherapies. 
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1. Introduction
The rising epidemic of obesity represents a major 
global challenge from both healthcare and economic 
perspectives. The impact of weight loss on improving 
the detrimental health consequences of obesity has 
been well documented. The role of pharmacother-
apy in the management of obesity is clearly estab-
lished. According to current guidelines pharmaco-
logical treatment should be considered as part of a 
comprehensive strategy of disease management for 
patients with a body mass index (BMI) ≥30 kg/m2 
or a BMI ≥27 kg/m2 with an obesity-related co-mor-
bidity such as type 2 diabetes, hypertension and/or 
dyslipidemia [1]. It should be emphasized that drugs 
are not a miraculous substitute for lifestyle change, 
but only an aid to facilitate the process of weight loss, 
as healthy eating habits and physical activity are a 
prerequisite for long-term weight loss maintenance. 
Anti-obesity drugs should be used according to their 
licensed indications and restrictions. The efficacy of 
pharmacotherapy should be evaluated after the first 3 
months of therapy. If weight loss is considered unsat-
isfactory (<5% of weight loss), treatment should be 
discontinued [2].
2. History of pharmacotherapy for obesity
The history of obesity pharmacotherapy is a his-
tory of withdrawals. Amongst the drugs marketed 
for weight loss there have been several instances of 
market withdrawal due to serious adverse events. 
Several examples of agents involved include fen-
fluramine, phenylpropanolamine, amphetamines, 
and most recently, rimonabant and sibutramine [3]. 
Fenfluramine was recalled from the market due to 
concerns of an increased prevalence of valvular heart 
disease and the possible association with primary 
pulmonary hypertension. Phenylpropanolamine was 
withdrawn due to an increased risk of hemorrhagic 
stroke, and amphetamines due to their abuse poten-
tial. Rimonabant and sibutramine are the latest in a 
series of centrally acting drugs that were withdrawn 
from the market because of side effects. Rimonabant, 
a cannabinoid receptor agonist, was approved as an 
anti-obesity drug in 2006. However, three years later 
the drug was suspended from the European union 
(EU) market due to an increased risk of psychiatric 
disorders, including major depression and suicidal 
ideation [4]. Sibutramine is a centrally acting neuro-
transmitter reuptake inhibitor that reduces the reup-
take of serotonin, norepinephrine, and dopamine, 
thereby increasing the levels of these substances in 
synaptic clefts. Owing to its appetite-suppressing 
effects, sibutramine was approved for weight man-
agement in patients unable to lose weight by diet and 
exercise alone. Concerns were raised regarding the 
safety of sibutramine, following reports of increased 
systolic and diastolic blood pressure and heart rate. 
The SCOUT (Sibutramine Cardiovascular OUTcomes) 
trial evaluated the long-term effects of sibutramine on 
the rates of cardiovascular events and death among 
10742 subjects with high cardiovascular risk [5]. The 
risk of a primary outcome event (composite of nonfa-
tal MI, nonfatal stroke, cardiac arrest, and CV death) 
was increased by 16% in the sibutramine group as com-
pared with the placebo group. This increase was due 
to a higher incidence of nonfatal myocardial infarc-
tion and stroke, with no significant difference between 
the study groups in the incidence of cardiovascular 
death or death from any cause. In 2010, the European 
Medicines Agency (EMA) recommended suspension of 
marketing authorizations for sibutramine based on the 
SCOUT study results.
With this background, regulatory authorities demand 
appropriate evidence of a very favorable benefit-risk 
ratio for any new drug, imposing strict criteria on its 
effectiveness and safety. Having in mind that weight 
loss medication is widely used and most patients 
require long-term treatment, post-marketing studies, 
including long-term cardiovascular outcome trials are 
necessary to assess the effect of a drug on the risk of 
major adverse cardiac events. 
The EMA and the US Food and Drug Administration 
(FDA) differ in their criteria on efficacy of anti-obesity 
drugs. According to the FDA, a product can be consid-
ered effective for weight management if after 1 year of 
treatment the difference in mean weight loss between 
the active-product and placebo-treated groups is at 
least 5% and if the proportion of subjects who lose ≥5% 
of baseline body weight in the active-product group is 
at least 35% or approximately double the proportion 
in the placebo-treated group [6]. In contrast, the EMA 
regards weight reduction from baseline as being more 
clinically relevant than placebo-subtracted weight loss, 
and requires evidence of at least 10% weight loss from 
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baseline body weight at 1 year, which must also be 
at least 5% greater than that achieved in the placebo 
group. The EMA guidelines also state that when the 
clinical response is at least 10% weight loss from base-
line body weight at the end of 1 year, the proportions 
of responders in various treatment arms could be con-
sidered as an alternative primary efficacy criterion [6]. 
Therefore, it is not surprising that drugs approved for 
the treatment of obesity in the US are not always avail-
able on the European market.
3. Currently approved weight loss medication
Pharmacological approaches to weight reduction 
focus on reducing energy intake (by decreasing food 
absorption or by decreasing appetite), increasing 
energy expenditure, or a combination of both effects 
[4]. There are two broad categories into which cur-
rent anti-obesity agents can be divided. Centrally 
acting drugs modulate signaling pathways in the 
central nervous system (CNS) and thus suppress 
appetite. Peripherally acting agents promote weight 
loss by reducing the absorption of nutrients, as for 
example, orlistat (Xenical®), an inhibitor of pancre-
atic lipases that blocks fat absorption from the gut. 
Until recently, orlistat was the only medication reg-
istered for the treatment of obesity in Europe. A 
deeper understanding of the complex mechanisms 
underlying obesity lead to the development of new 
targets for pharmacotherapeutic interventions. After 
a long time, in 2015, two new anti-obesity drugs were 
approved in Europe. These are a fixed combination 
of naltrexone/bupropion (Mysimba®) and liraglu-
tide at a dose of 3.0 mg (Saxenda®). In addition to 
the above-mentioned agents, two other drugs have 
been introduced into the US market. Although, the 
FDA approved lorcaserin (Belviq®) and a fixed com-
bination of phentermine/topiramate (Qsymia®) in 
2012, the EMA did not approve their use in the EU. 
Moreover, medications for the short-term treatment 
of obesity, such as diethylpropion and phentermine in 
monotherapy, are also available in the US, but not in 
the EU. However, such agents that cannot be used for 
longer than three months do not fit into the rational 
paradigm for the treatment of obesity as a chronic 
disease. Table 1. provides an overview of medications 
currently approved in the EU and/or US for the long-
term treatment of obesity in adults.
3.1 orlistat 
Orlistat is a reversible inhibitor of pancreatic lipase, 
which reduces the absorption of fat from the gut. At 
the standard prescription dose of 120 mg three times 
daily before meals, orlistat prevents approximately 
30% of dietary fat from being absorbed, thereby 
reducing caloric intake [7]. It is marketed as a pre-
scription drug under the trade name Xenical® and is 
sold over-the-counter as Alli® which is one-half the 
strength of Xenical. The most common side effects 
are gastrointestinal due to unabsorbed fats in the 
intestine, which can include steatorrhea, frequent 
bowel movements, and fecal incontinence. Because 
the absorption of fat-soluble vitamins is inhibited by 
Table 1. Medications currently approved in the European Union and/or United States for long-term 
obesity treatment in adults
Generic name Trade name Approved in EU Approved in US
orlistat Xenical/Alli* YES YES
lorcaserin Belviq NO YES
phentermine/topiramate Qsymia NO YES
naltrexone/bupropion Contrave/Mysimba** YES YES
liraglutide 3.0 mg Saxenda YES YES
*Alli® is available OTC and one-half the strength of Xenical® which is available by prescription only **Contrave® is trade name 
of naltrexone/bupropion in US and Mysimba® in EU
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orlistat, vitamin A, D, E and K supplements should 
be taken when using orlistat. The effectiveness of orl-
istat in promoting weight loss is modest. Pooled data 
from clinical trials suggest that people given orlistat 
in addition to lifestyle modifications, such as diet and 
exercise, lose about 2-3 kg more than those taking 
placebo [8]. Orlistat modestly reduces blood pres-
sure, has favorable effects on obesity-related meta-
bolic disorders, and appears to prevent the onset of 
type 2 diabetes. Data from the XENDOS (XENical in 
the prevention of Diabetes in Obese Subjects) trial of 
3305 patients followed for up to 4 years, found that 
orlistat use decreased body weight by 2.7 kg (approx-
imately 2.4% of initial body weight) more than pla-
cebo and significantly decreased the risk for devel-
oping type 2 diabetes. The cumulative incidence of 
diabetes was 9.0% with placebo and 6.2% with orl-
istat, corresponding to a risk reduction of 37.3% [9]. 
Unpleasant side effects and a modest weight loss sig-
nificantly limit the wider use of orlistat.
3.2 lorcaserin
Lorcaserin is a centrally acting selective agonist of 
the serotonin type 2 C receptor (5-HT2C) that has 
been designed to exhibit positive effects of sero-
tonergic drugs, but without unwanted side effects 
mediated by serotonin receptor type 2A and 2B. 
Several clinical trials were conducted to evaluate 
the efficacy and safety of lorcaserin. In the 2-year, 
BLOOM (Behavioral Modification and Lorcaserin 
for Overweight and Obesity Management) trial, 3182 
obese or overweight adults (mean BMI 36.2 kg/m2) 
were randomized to receive lorcaserin 10 mg twice 
daily or placebo [10]. All patients also underwent 
a lifestyle intervention.  After one year, 47.5% of 
patients receiving lorcaserin had lost ≥5% of their 
baseline body weight, compared with 20.3% for those 
treated with placebo. Weight loss of at least 10% was 
achieved by 22.6% of patients receiving lorcaserin 
and 7.7% of patients in the placebo group. Patients 
in the lorcaserin group lost an average of 5.8 kg, as 
compared with 2.2 kg in the placebo group. Among 
patients in the lorcaserin group who had weight loss 
of 5% or more at year 1, the loss was maintained in 
a greater proportion of patients who continued to 
receive lorcaserin for a second year than in those who 
switched to placebo (67.9% vs. 50.3%). 
Similar results were reported in the 1-year BLOSSM 
trial that examined two doses of lorcaserin in a 
cohort of 4008 patients [11]. Significantly more 
patients treated with lorcaserin 10 mg/day and 20 
mg/day lost at least 5% of baseline body weight (47.2 
and 40.2%, respectively) as compared with placebo 
(25.0%). Weight loss of ≥10% was achieved in 22.6% 
and 17.4% of patients receiving lorcaserin 10 mg and 
20 mg, respectively, and 9.7% of patients in the pla-
cebo group. 
The BLOOM-DM (Behavioral Modification and 
Lorcaserin for Obesity and Overweight Management 
in Diabetes Mellitus) study evaluated efficacy and 
safety of lorcaserin for weight loss in patients with type 
2 diabetes [12]. Patients receiving lorcaserin 10 mg 
once or twice daily lost an average of 5% and 4.5% of 
their baseline body weight respectively, as compared 
with 1.5% in the placebo group. HbA1c decreased by 
approximately 1% with lorcaserin. Headaches, nau-
sea, and dizziness were the most common lorcaser-
in-related adverse events. Importantly, there was 
no evidence for an increase in clinically significant 
valvular heart disease in lorcaserin-treated patients 
compared with those receiving placebo. However, the 
drug has not been approved in Europe. 
The Committee for Medicinal Products for Human 
Use (CHMP) expressed concern about carcinogenic 
potential of lorcaserin, the development of psychiatric 
disorders, and possible damage to heart valves asso-
ciated with its long-term use. An increased incidence 
of mammary adenocarcinomas was observed during 
animal studies in female rats, which was associated 
with lorcaserin plasma exposures that were 87-times 
the daily human clinical dose [6]. The cancer risk 
in animal studies was a concern of the FDA when it 
rejected lorcaserin the first time. The development 
of potentially life-threatening serotonin syndrome 
or neuroleptic malignant syndrome-like reactions 
have been reported during use of serotonergic drugs 
[13]. Based on the mechanism of action of lorcaserin 
and the theoretical potential for serotonin syndrome, 
extreme caution should be employed when used in 
combination with other drugs that may affect the ser-
otonergic neurotransmitter systems, including, mon-
oamine oxidase inhibitors, selective serotonin reup-
take inhibitors, and tricyclic antidepressants. 
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Although the lorcaserin-related side effects are mild 
and rare, relatively modest effect on weight loss and 
the fear of possible adverse events during long-term 
use make the future of lorcaserin uncertain.
3.3 Phentermine/topiramate
Fixed combination of phentermine/topiramate 
extended-release (Qsymia®) came to the US market 
in September 2012. On the basis of the weight loss 
achieved with phentermine and topiramate as indi-
vidual agents, and the notion that a combination of 
these agents at low doses might have additive or syn-
ergistic effects, thereby providing improved efficacy 
and safety, a combination of phentermine/topiramate 
was developed for once-daily oral dosing to enhance 
weight loss and improve weight-related comorbidi-
ties [14]. In this low-dose formulation, phentermine 
is readily absorbed and immediately released to 
provide effects early in the day, whereas topiramate 
extended-release provides effects through later peri-
ods of the day. It is currently approved at doses of 
3.75 mg/23 mg, 7.5 mg/46  mg and 15 mg/92  mg for 
chronic weight management in obese and overweight 
adults with at least one weight-related comorbidity 
[15].
Phentermine is a centrally acting sympathomi-
metic agent, which mainly acts to increase norepi-
nephrine in the CNS, thereby suppressing appetite. 
Phentermine has been available as monotherapy 
since 1956 for the short-term treatment of obesity, 
mainly in markets outside of Europe. Topiramate 
is an antiepileptic drug marketed since 1996. Eight 
years later, it was approved and most frequently pre-
scribed for the prevention of migraines. Because 
trials of its efficacy in patients with seizures noted 
significant weight loss, topiramate was further evalu-
ated for the treatment of obesity. Although the exact 
mechanism of action responsible for the weight loss 
is not fully understood, animal studies suggest that 
topiramate antagonizes glutamate action at α-ami-
no-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors/kainate receptors and augments 
γ-aminobutyric acid (GABAA) receptor-mediated 
inhibitory currents [16]. Topiramate also appears 
to inhibit voltage-dependent sodium channels, cal-
cium channels, and carbonic-anhydrase isoenzymes 
II and IV. Topiramate may decrease food intake 
through effects on carbonic-anhydrase by altering 
taste or through its effects on GABA transmission, 
since GABAA receptor activation and the interaction 
between GABA and leptin pathways are known to 
mediate effects on appetite and metabolism [17]. 
Three phase III randomized, placebo-controlled 
trials evaluated the safety and efficacy of phenter-
mine-topiramate combination in the treatment 
of obesity. The EQUIP trial evaluated 1267 obese 
patients with mean baseline BMI of 42.1 kg/m2 over 
a 56-week period [18]. Patients were divided into 3 
treatment arms: one receiving 3.75 mg/23 mg phen-
termine-topiramate, the second receiving 15 mg/92 
mg combination, and the third receiving placebo. At 
56 weeks, patients in the high dose, low dose, and 
placebo groups, lost 10.9%, 5.1%, and 1.6% of base-
line body weight, respectively. Moreover, percent-
ages of patients losing ≥5%, ≥10% and ≥15% of body 
weight were, respectively, 66.7%, 47.2%, and 32.3% 
on high dose; 44.9%, 18.8%, and 7.3% on low dose; 
and 17.3%, 7.4%, and 3.4% on placebo.  
In the 56-week CONQUER trial, 2487 overweight or 
obese adults, with a BMI of 27-45 kg/m2 and two or 
more obesity-related comorbidities were randomly 
assigned to once-daily medium dose (7.5 mg/46.0 
mg), high dose (15.0 mg/92.0 mg) phentermine/
topiramate or placebo [19]. All subjects received 
standardized counseling for diet and lifestyle mod-
ification. The average weight loss after 56 weeks 
was 9.8% in the high dose phentermine/topiramate 
group, 7.8% in the medium dose group, and 1.2% 
in the placebo group. In addition, 70% and 48% of 
patients given high dose phentermine/topiramate, 
62% and 37% given medium dose, and 21% and 7% 
in the placebo group, lost ≥5% and ≥10% of initial 
weight, respectively. The SEQUEL study, an exten-
sion of the CONQUER study, confirmed the sus-
tained weight loss over the period of two years along 
with improvements in cardiometabolic profiles [20]. 
After two years, patients receiving medium dose and 
high dose phentermine/topiramate achieved a weight 
loss of 9.3% and 10.7%, respectively.  
Side effects of combination phentermine/topiramate 
are consistent with previously known side effects of 
phentermine monotherapy (dry mouth, constipation, 
insomnia, palpitations) or topiramate (dizziness, 
paresthesia, dysguesia, disturbance of concentration, 
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metabolic acidosis, kidney stones). Other worrisome 
side effects are teratogenicity, increase in resting 
heart rate, anxiety, and depression. 
Data from pregnancy registries and epidemiology 
studies indicate that a fetus exposed to topiramate 
in the first trimester of pregnancy has an increased 
risk of oral clefts (cleft lip with or without cleft pal-
ate). Females of reproductive potential should have 
a negative pregnancy test before starting phenter-
mine/topiramate and monthly tests thereafter during 
therapy. Females of reproductive potential should 
also use effective contraception during phentermine/
topiramate therapy. If pregnancy occurs, the treat-
ment should be discontinued immediately. A small 
increase in resting heart rate has been observed in 
clinical trials of phentermine/topiramate at higher 
doses, with more patients on top-dose (56.1%) than 
placebo (42.1%) having increases of more than 10 
beats per minute, leading to some concerns regard-
ing its potential long-term effect on cardiovascular 
events [21]. The labeling suggests regular monitoring 
of resting heart rate and recommends against pre-
scription in patients with recent or unstable cardiac 
or cerebrovascular disease. Phentermine/topiramate 
should not be taken during or within 14 days of tak-
ing monoamine oxidase inhibitors and in patients 
with glaucoma. 
Given the extremely favorable effect on body weight, 
which is significantly higher compared to other 
currently available anti-obesity drugs, the FDA has 
concluded that the benefits of the drug exceeds the 
potential risks and has approved its use for the treat-
ment of obesity. However, the EMA again had a dis-
senting opinion highlighting concerns over possible 
long-term cardiovascular and CNS adverse effects, 
teratogenic risk, and possible drug misuse among 
people to whom it should not have been prescribed.
3.4 naltrexone/bupropion 
The fixed combination of naltrexone/bupropion sus-
tained-release was approved by the FDA in September 
2014 under the brand name Contrave®, and then in 
May 2015 in the EU where it is presently available 
under the name Mysimba®. 
Naltrexone is an opioid antagonist with a high affin-
ity for the μ-opioid receptor. As monotherapy, nal-
trexone has been approved for the treatment of 
alcoholism and opioid addiction.  Bupropion is an 
atypical antidepressant, which inhibits reuptake of 
dopamine and norepinephrine. It is approved as an 
aid in smoking cessation and for the treatment of 
depression [22]. 
Neuronal networks originating in the hypothalamus 
play fundamental roles in the control of energy bal-
ance. The proopiomelanocortin (POMC) containing 
neurons are the most important source of anorexi-
genic signals. POMC is cleaved into peptides includ-
ing α-melanocyte stimulating hormone (α-MSH) 
and β-endorphin, which are co-released from POMC 
cells. α-MSH stimulates the melanocortin-4 recep-
tor, which leads to decreased food intake, increased 
energy expenditure, and weight loss. β-endorphin 
binds to the inhibitory μ-opioid receptor on POMC 
cells and acts like a brake to reduce activity of POMC 
cells. Bupropion stimulates activity of POMC cells, 
increasing POMC production and secretion of 
α-MSH and β-endorphin. Naltrexone blocks β-en-
dorphin action at the μ-opioid receptor, thus pre-
venting autoinhibition of POMC neurons. Together, 
the naltrexone/bupropion combination produces a 
greater increase in POMC activity, which leads to 
weight loss [23].
Several clinical trials were conducted to evaluate 
the efficacy and safety of fixed combination naltrex-
one/bupropion. In the Contrave Obesity Research-I 
(COR-I) trial, 1742 obese or overweight participants 
were randomly assigned to receive sustained-release 
naltrexone 32 mg plus bupropion 360 mg (NB32), 
sustained-release naltrexone 16 mg plus bupropion 
360 mg (NB16), or placebo [24]. At 56 weeks, mean 
change in bodyweight was -6.1% in NB32 group, 
-5.0% in the NB16 group, and -1.3% in the placebo 
group. Weight loss of ≥ 5% was achieved by 48% 
of patients receiving NB32, 39% of those receiving 
NB16, and 16% of patients in the placebo group.
Contrave Obesity Research-II (COR-II) was a dou-
ble-blind, placebo-controlled study of 1496 partici-
pants with mean baseline BMI of 36 kg/m2 who were 
randomized to combined naltrexone/bupropion 32 
mg/360 mg (NB32) or placebo for up to 56 weeks 
[25]. Significantly greater weight loss was observed 
with NB32 versus placebo at week 28 (-6.5% vs. 
-1.9%) and week 56 (-6.4% vs. -1.2%). Weight loss 
of ≥ 5% was achieved by 55.6% of patients receiving 
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NB32 and 17.5% receiving placebo at week 28, and 
by 50.5% of patients receiving NB32 versus 17.1% of 
patients in the placebo group at week 56. NB32 pro-
duced greater improvements in cardiometabolic risk 
markers. Naltrexone/bupropion was not associated 
with increased depression or suicidality compared 
with placebo.
COR-BMOD trial examined the efficacy and safety 
of naltrexone plus bupropion as an adjunct to inten-
sive behavior modification (BMOD) [26]. A total of 
793 participants (mean BMI of 36.5 kg/m²) were ran-
domly assigned to: placebo plus BMOD or NB32 plus 
BMOD. Both groups were prescribed an energy-re-
duced diet and 28 group BMOD sessions. At week 56, 
weight loss was 5.1% with placebo + BMOD vs. 9.3% 
with NB32 + BMOD. 
The most frequent adverse events of naltrexone/
bupropion are nausea, headache, constipation, diz-
ziness, vomiting, and dry mouth. Contraindications 
include uncontrolled hypertension, current seizure 
disorder or a history of seizures, CNS tumor, acute 
alcohol or benzodiazepine withdrawal, history of 
bipolar disorder, chronic opiate or opiate agonists 
therapy, acute opiate withdrawal, and concomitant 
administration of monoamine oxidase inhibitors 
(MAOI) [27]. At least 14 days should elapse between 
discontinuation of MAOI and initiation of treatment 
with naltrexone/bupropion.  
The combination of naltrexone/bupropion is available 
as sustained-release tablets containing 8 mg of nal-
trexone and 90 mg of bupropion. Treatment begins 
by taking one tablet daily, and gradually increasing 
doses up to 4 weeks at the recommended dose of two 
tablets taken twice daily. Treatment should be dis-
continued after 16 weeks if patients have not lost at 
least 5% of their initial body weight.
3.5 liraglutide 
Incretin-based therapies represent a significant step 
forward in the treatment of type 2 diabetes, and most 
recently in the treatment of obese people with or 
without diabetes. Incretins are gut-derived hormones 
that are secreted from enteroendocrine cells into the 
bloodstream in response to ingestion of food. The 
most extensively studied incretin is glucagon-like 
peptide-1 (GLP-1) with a beneficial role in the con-
trol of glucose and energy homeostasis [28]. As native 
GLP-1 has a very short circulating half-life due to 
degradation by the enzyme DPP-4, degradation-re-
sistant GLP-1 receptor agonists have been developed. 
Liraglutide, a long-acting GLP-1 receptor agonist 
with 97% homology to native GLP-1, is approved for 
the treatment of type 2 diabetes. It is an injectable 
drug that is administrated at doses up to 1.8 mg once 
daily. Based on the results of clinical trials in patients 
with type 2 diabetes, as well as studies that have inves-
tigated the therapeutic potential of higher doses of 
the drug in obese patients without diabetes, liraglu-
tide at dose of 3.0 mg received approval by the FDA 
and EMA for treatment of obesity in adults under the 
brand name Saxenda®. Weight loss with liraglutide is 
mediated by reduced appetite and energy intake [29].
Astrup at al. conducted a double-blind, placebo-con-
trolled 20-week trial, with open-label orlistat com-
parator [30]. A total of 564 individuals were ran-
domly assigned to one of four liraglutide doses (1.2 
mg, 1.8 mg, 2.4 mg, or 3.0 mg) or to placebo admin-
istered once a day subcutaneously, or orlistat 120 mg 
three times a day orally. All subjects were advised to 
reduce daily caloric intake by 500 kcal and to increase 
the level of physical activity. Mean weight loss with 
liraglutide 1.2-3.0 mg was 4.8 kg, 5.5 kg, 6.3 kg, and 
7.2 kg, respectively, compared with 2.8 kg with pla-
cebo and 4.1 kg with orlistat. Weight loss >5% was 
achieved in more patients (76%) taking liraglutide 
3.0 mg than placebo (30%) or orlistat (44%). 
In the SCALE trial, 3731 overweight or obese adults 
without diabetes were randomized to treatment 
with liraglutide 3.0 mg or placebo, and both groups 
received counseling on lifestyle modification [31]. 
After 56 weeks, significantly greater weight loss was 
observed with liraglutide as compared with placebo 
(-8.0% vs. -2.6%). The proportion of patients that 
lost ≥5% or ≥10% of body weight was 63% and 33%, 
respectively in the liraglutide group, and 27% and 
11%, respectively, in the placebo group. Moreover, 
63% and 33% in the liraglutide group, as compared 
with 27% and 11% in the placebo group, lost at least 
5% and 10% of their body weight, respectively. 
Wadden et al. assessed the efficacy of liraglutide in 
maintaining weight loss achieved with a low-calorie 
diet (LCD) [32]. Participants who lost ≥5% of initial 
weight during a LCD run-in were randomly assigned 
to liraglutide 3.0 mg per day or placebo for 56 weeks. 
More participants receiving liraglutide (81.4%) 
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maintained the ≥5% run-in weight loss, compared 
with those receiving placebo (48.9%), and 50.5% 
patients in the liraglutide group versus 21.8% of 
patients in the placebo group lost ≥5% of randomiza-
tion weight. This study showed that liraglutide holds 
promise for improving weight loss maintenance. 
Liraglutide is generally well tolerated. Mild to mod-
erate nausea and vomiting are the major side effects 
of the drug and are usually transient, but may con-
tribute to the greater weight loss [33]. Regarding the 
controversy of whether GLP-1–based therapy can 
increase the risk for specific malignant disease like 
pancreatic carcinoma and thyroid cancer, there is no 
firm evidence in favor of this hypothesis; however, 
long-term safety observations are needed [34].  
The initial dose of liraglutide is 0.6 mg s.c. daily, and 
is increased by 0.6 mg/day in weekly intervals until a 
dose of 3.0 mg/day is achieved. Treatment should be 
discontinued after 12 weeks on the 3.0 mg/day dose if 
patients have not lost at least 5% of their initial body 
weight. 
4. Conclusion
Although lifestyle modifications aimed at reducing 
calorie intake and increasing energy expenditure 
remain the cornerstone of obesity management, 
pharmacotherapy can serve as a useful adjunct. 
Recent advances in our understanding of energy 
homeostasis and its complexity, have resulted in the 
new pharmacological approaches for obesity treat-
ment. However, our knowledge of adverse effects that 
result from their long-term use is still incomplete. 
The burden of previous weight loss pharmacother-
apy that has been withdrawn due to safety concerns, 
underlines the need for caution and close follow-up 
of patients undergoing pharmacological interven-
tions for obesity treatment.
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